CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lymphomas: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD123-targeted CAR-NK overview
The therapeutic is under development for the treatment of relapsed and refractory acute myeloid leukemia lymphoma and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The therapeutic candidate comprises of NK cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing CD123. It is administered through intravenous route.
For a complete picture of CD123-targeted CAR-NK’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#CD123targeted #CARNK #Chongqing #Precision #Biotech #Natural #Killer #Cell #Lymphomas #Likelihood #Approval
